Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies
- PMID: 19141028
- PMCID: PMC2711257
- DOI: 10.1111/j.1478-3231.2008.01957.x
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies
Abstract
Background: Although there are many studies of the predictors of death in hepatocellular carcinoma (HCC), most combine patients with and without cirrhosis and many combine those with compensated and decompensated cirrhosis.
Objective: To perform a systematic review of the literature evaluating the predictors of death in patients with cirrhosis and HCC and to evaluate whether the predictors differ between patients with compensated and decompensated cirrhosis.
Inclusion criteria: (i) publication in English, (ii) adult patients, (c) >80% of the patients had cirrhosis, (iv) follow-up >6 months and (v) multivariable analysis. Quality was based on the accepted quality criteria for prognostic studies.
Results: Of the 1106 references obtained, 947 were excluded because they did not meet the inclusion criteria. A total of 23 968 patients were included in 72 studies (median, 177/study); 77% male, median age 64, 55% Child-Pugh class A. The most robust predictors of death were portal vein thrombosis, tumour size, alpha-foetoprotein and Child-Pugh class. Sensitivity analysis using only 15 'good' studies and 22 studies in which all patients had cirrhosis yielded the same variables. In the studies including mostly compensated or decompensated patients, the predictors were both liver and tumour related. However, these studies were few and the results were not robust.
Conclusions: This systematic review of 72 studies shows that the most robust predictors of death in patients with cirrhosis and HCC are tumour related and liver related. Future prognostic studies should include these predictors and should be performed in specific patient populations to determine whether specific prognostic indicators are more relevant at different stages of cirrhosis.
Figures
Comment in
-
Prognostic scores for hepatocellular carcinoma: none is the winner.Liver Int. 2009 Apr;29(4):478-80. doi: 10.1111/j.1478-3231.2009.01994.x. Liver Int. 2009. PMID: 19323777 Free PMC article. No abstract available.
Similar articles
-
Hypergammaglobulinemia is a strong predictor of disease progression, hepatocellular carcinoma, and death in patients with compensated cirrhosis.Liver Int. 2018 Jul;38(7):1220-1229. doi: 10.1111/liv.13649. Epub 2018 Jan 8. Liver Int. 2018. PMID: 29194934
-
Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy.Cancer. 2001 Jul 1;92(1):126-35. doi: 10.1002/1097-0142(20010701)92:1<126::aid-cncr1300>3.0.co;2-v. Cancer. 2001. PMID: 11443618
-
Survival improvement in Child-Pugh C cirrhotic patients with hepatocellular carcinoma diagnosed during 1990-2002.Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):288-96. doi: 10.1016/j.gcb.2010.01.005. Epub 2010 Feb 26. Gastroenterol Clin Biol. 2010. PMID: 20189339
-
Clinical staging of hepatocellular carcinoma.Dig Dis. 2009;27(2):131-41. doi: 10.1159/000218345. Epub 2009 Jun 22. Dig Dis. 2009. PMID: 19546551 Review.
-
[Hepatic resection for hepatocellular carcinoma--results and analysis of the current literature].Zentralbl Chir. 2009 Apr;134(2):127-35. doi: 10.1055/s-0028-1098881. Epub 2009 Apr 20. Zentralbl Chir. 2009. PMID: 19382043 Review. German.
Cited by
-
Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort Study.J Oncol. 2020 May 28;2020:4835653. doi: 10.1155/2020/4835653. eCollection 2020. J Oncol. 2020. PMID: 32565803 Free PMC article.
-
Impact of apolipoprotein A1 on tumor immune microenvironment, clinical prognosis and genomic landscape in hepatocellular carcinoma.Precis Clin Med. 2023 Sep 2;6(3):pbad021. doi: 10.1093/pcmedi/pbad021. eCollection 2023 Sep. Precis Clin Med. 2023. PMID: 38025972 Free PMC article.
-
Nuclear medicine radiomics in digestive system tumors: Concept, applications, challenges, and future perspectives.View (Beijing). 2023 Dec;4(6):20230032. doi: 10.1002/VIW.20230032. Epub 2023 Jul 28. View (Beijing). 2023. PMID: 38179181 Free PMC article.
-
Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis.BMC Gastroenterol. 2023 Dec 19;23(1):450. doi: 10.1186/s12876-023-03085-8. BMC Gastroenterol. 2023. PMID: 38114915 Free PMC article.
-
Mast cells, disease and gastrointestinal cancer: A comprehensive review of recent findings.Transl Gastrointest Cancer. 2012 Jul 1;1(2):138-150. Epub 2012 Feb 8. Transl Gastrointest Cancer. 2012. PMID: 22943044 Free PMC article.
References
-
- Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463–72. - PubMed
-
- D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–31. - PubMed
-
- Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918–2. - PubMed
-
- A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998;28:751–5. - PubMed
-
- Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical